Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607395 | 0.86 | CNR2 (0.57) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL8942396 | 0.85 | VEGFA (0.57) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL1606703 | 0.85 | CA12 (0.67) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL9022567 | 0.83 | CNR2 (0.57) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL4674665 | 0.81 | CA12 (0.52) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL4674670 | 0.81 | CA12 (0.52) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL24434943 | 0.80 | KDM4E (0.49) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL9022216 | 0.80 | HDAC8 (0.57) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL9022757 | 0.80 | HDAC3 (0.51) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL9022464 | 0.79 | CNR2 (0.46) | EPHX2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | EPHX2 3730/4885CA12 4746/4885CA1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.